TITLE

FDA Warnings Dominate Pharmaceutical News

AUTHOR(S)
Elliott, William T.
PUB. DATE
January 2008
SOURCE
Travel Medicine Advisor;Jan2008, Vol. 18 Issue 1, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
In this issue: FDA warnings for existing drugs dominate pharmaceutical news this month. The FDA and its advisory committees have issued warnings on erythropoiesis-stimulating agents, oseltamivir (Tamiflu) and zanamivir (Relenza) for the treatment of influenza, rosiglitazone (Avandia) for the treatment of type 2 diabetes, varenicline (Chantix) to help stop smoking, the beta agonist salmeterol (Serevent), and modafinil (Provigil) for use in children. The FDA has also asked for marketing suspension of Bayer's aprotinin (Trasylol). These warnings represent a new push by the FDA to regulate existing drugs for safety after they have been approved for marketing. It also comes at a time when the FDA is cleaning up its advisory committee processes, especially with regard to limiting potential conflict of interest by advisory committee members. A summary of the new committee processes can be found at www.FDA.gov.
ACCESSION #
28720242

 

Related Articles

  • FDA Warnings Dominate Pharmaceutical News. Elliott, William T. // Clinical Cardiology Alert;Jan2008, Vol. 27 Issue 1, Special section p1 

    FDA warnings for existing drugs dominate pharmaceutical news this month. The FDA and its advisory committees have issued warnings on erythropoiesis-stimulating agents, oseltamivir (Tamiflu) and zanamivir (Relenza) for the treatment of influenza, rosiglitazone (Avandia) for the treatment of type...

  • US to keep rosiglitazone on market.  // Pulse;8/2/2007, Vol. 67 Issue 29, p2 

    The article reports on the decision of the U.S. Food and Drug Administration (FDA) to keep rosiglitazone on the market, despite new research adding to concerns over its adverse effect on the heart. An advisory panel convened by the FDA voted 22 to one to allow continued marketing of the drug,...

  • FACTS AND FRICTIONS: CONFLICTS OF INTEREST IN MEDICAL RESEARCH. DeAngelis, Catherine // Methodist DeBakey Cardiovascular Journal;Dec2011, Vol. 7 Issue 4, p24 

    The article discusses the implication of conflict of interest in medical research on the field of medicine. It defines conflict of interest as conflict between private interests and official responsibility of a person in a position of trust. It cites financial conflict of interest which involves...

  • Full disclosure. Nash, Karen // Dermatology Times;Jun2009, Vol. 30 Issue 6, p12 

    The article focuses on the reactions of the dermatologists regarding the exclusion of the conflict of interest information in new drug marketing applications required by the Food and Drug Administration (FDA) in the U.S. Most of the dermatologists agreed that this information is important and is...

  • Hemostatic agent suspended from market.  // Pharmacy Today;Dec2007, Vol. 13 Issue 12, p1 

    The article reports on the agreement between the U.S. Food and Drug Administration and Bayer Pharmaceuticals Corp. to suspend the marketing of aprotinin. This is due to preliminary findings indicating an increased risk of death associated with its use. Aprotinin is a drug used to reduce the...

  • Actos.  // Pharmaceutical Representative;Oct2010, Vol. 40 Issue 10, p10 

    The article reports on the safety review of the diabetic drug, Actos (pioglitazone), conducted by the U.S. Food and Drug Administration (FDA) to determine the association between Actos and the risk of bladder cancer.

  • Concerns about Rezulin grow even stronger. Cerrato, Paul L. // RN;Jul99, Vol. 62 Issue 7, p92 

    Reports on the precautions issued by the United States Food and Drug Administration on the use of antidiabetic agent troglitazone.

  • FDA approved saxagliptin to treat type 2 diabetes.  // Hem/Onc Today;9/10/2009, Vol. 10 Issue 17, p34 

    The article announces that the U.S. Food and Drug Administration (FDA) has approved saxagliptin, an oral hypoglycemic drug, as a treatment for type 2 diabetes.

  • Market watch: Upcoming market catalysts in Q1 of 2010. Rosenthal, Jesse // Nature Reviews Drug Discovery;Jan2010, Vol. 9 Issue 1, p11 

    The article forecasts the drug discovery catalysts in the U.S. in the first quarter of 2010. It expects the Food and Drug Administration (FDA) to decide on marketing applications for drugs that could advance treatment in their specific indications in this quarter. It notes that the potential...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics